1832 Asset Management
NBIX icon

1832 Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

1832 Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-9,492
Closed -$1.35M – 706
2025
Q4 		$1.35M Sell
9,492
-1,295
-12% -$188K ﹤0.01% 555
2025
Q3 		$1.51M Buy
10,787
+1,289
+14% +$175K ﹤0.01% 535
2025
Q2 		$1.19M Buy
+9,498
New +$1.09M ﹤0.01% 553
2024
Q3 		– Sell
-541,200
Closed -$74.5M – 820
2024
Q2 		$74.5M Buy
541,200
+504,400
+1,371% +$69.2M 0.06% 155
2024
Q1 		$5.08M Sell
36,800
-4,200
-10% -$574K ﹤0.01% 380
2023
Q4 		$5.4M Buy
+41,000
New +$4.72M 0.01% 379
2023
Q1 		– Sell
-691,400
Closed -$82.6M – 947
2022
Q4 		$82.6M Buy
691,400
+216,500
+46% +$25.4M 0.14% 132
2022
Q3 		$50.4M Buy
474,900
+397,500
+514% +$40.3M 0.09% 186
2022
Q2 		$7.54M Buy
+77,400
New +$7.14M 0.01% 398
2020
Q3 		– Sell
-205,600
Closed -$25.5M – 715
2020
Q2 		$25.5M Sell
205,600
-350,700
-63% -$38.8M 0.08% 171
2020
Q1 		$49.9M Sell
556,300
-81,600
-13% -$7.99M 0.18% 115
2019
Q4 		$67.3M Buy
637,900
+107,800
+20% +$11.3M 0.2% 103
2019
Q3 		$46.8M Buy
+530,100
New +$49.5M 0.15% 128
2018
Q4 		– Sell
-658,700
Closed -$79.2M – 695
2018
Q3 		$79.2M Buy
658,700
+271,300
+70% +$30.8M 0.26% 92
2018
Q2 		$37M Buy
+387,400
New +$34.7M 0.13% 140
2018
Q1 		– Sell
-63,700
Closed -$4.92M – 720
2017
Q4 		$4.92M Buy
+63,700
New +$4.34M 0.02% 292

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

1832 Asset Management's NBIX Position: Q1 2026 in Review

1832 Asset Management sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 9,492 shares — an estimated $1.35M sold.

1832 Asset Management first reported a position in NBIX in Q4 2017 and held it in 16 quarters. The position peaked at $82.6M in Q4 2022. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • 1832 Asset Management reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
  • 1832 Asset Management sold 9,492 Neurocrine Biosciences shares in Q1 2026, an estimated $1.35M.
  • 1832 Asset Management first reported a position in Neurocrine Biosciences in Q4 2017 and held it in 16 quarters.
  • 1832 Asset Management's Neurocrine Biosciences position peaked at $82.6M in Q4 2022.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on 1832 Asset Management's 13F filing for Q1 2026, filed 14 May 2026.